| Species |
Human |
| Protein Construction |
IL-6R (Leu20-Phe365)
Accession # P08887 |
|
| Purity |
> 95% as analyzed by SDS-PAGE
> 95% as analyzed by HPLC |
| Endotoxin Level |
< 0.2 EU/μg of protein by gel clotting method |
| Biological Activity |
ED50 < 0.2 μg/ml, measured in a cell proliferation assay using M1 cells in the presence of 10.0 ng/ml human IL-6. |
| Expression System |
CHO |
| Apparent Molecular Weight |
54~56 kDa, on SDS-PAGE under reducing conditions. |
| Formulation |
Lyophilized after extensive dialysis against PBS. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH?O or PBS up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
ED??< 0.2 μg/ml, measured in a cell proliferation assay using M1 cells in the presence of human IL-6.
| Target Background |
Interleukin-6 Receptor Alpha, also known as IL-6RA, IL-6R1 and CD126, belongs to the type I cytokine receptor family. It is mainly expressed on T cells, fibroblasts and macrophages. IL-6RA couples with gp130 to form the IL-6 receptor; IL-6RA binds specifically to IL-6 and depends on gp130 to transmit signals. IL-6RA dysfunction has been correlated with the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases and prostate cancer. Soluble IL-6RA, which consists of only the extracellular domain of IL-6RA, acts as an agonist of IL-6 activity. |
| Synonyms |
IL-6RA; IL-6R1; CD126; IL-6RA |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
